Your session is about to expire
← Back to Search
Treatment for Ovarian Cancer (BriTROC-2 Trial)
Summary
In BriTROC-2, up to 250 women with a confirmed diagnosis of high-grade serous/high-grade endometrioid or carcinosarcoma will be eligible for full consent (Part 2) and registration to BriTROC-2 and will be followed prospectively until first relapse. Women with presumed newly-diagnosed high-grade serous carcinoma of the ovary, fallopian tube or peritoneum can be approached for consent to Part 1 (screening consent) of BriTROC-2 prior to formal diagnosis. The aim of this study is to acquire tumour material at diagnosis and relapse, whole blood for genomic analysis and plasma for ctDNA. This study will also isolate single cells and establish organoid cultures from ascites/peritoneal washings.
- Ovarian Cancer
- Serous Carcinoma
- Ovarian Carcinosarcoma
- Peritoneal Carcinoma
- BRCA1
- BRCA2 Mutation
Timeline
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Awards & Highlights
Find a Location
Who is running the clinical trial?
Share this study with friends
Copy Link
Messenger